Adocia

Capital/Financing Update • Sep 17, 2015

PRESS RELEASE

ADOCIA: additional contribution to the liquidity agreement

Lyon, France, September 17, 2015 - Adocia (Euronext Paris: FR0011184241 - ADOC) today announced an increase of EUR 200,000, effective as of September 17, 2015, to the means allocated to the liquidity agreement with Kepler Capital Markets S.A.

As a reminder, as of June 30, 2015, the following resources were allocated to the liquidity account:

• 2,257 shares of Adocia and
• 83,378.96 euros in cash.

This liquidity agreement, complying with the charter of ethics established by the French Financial Markets Association (A.M.A.F.I.) and approved by the French market authority (Autorité des marchés financiers) effective on March 21, 2011, aims to ensure the liquidity of ADOCIA company's shares on the regulated market Euronext Paris.

About Adocia

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. It has a particularly strong expertise in the field of insulins. Adocia's proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients. To learn more about Adocia, please visit us at www.adocia.com.

For more information please contact:

Adocia	Adocia Press Relations
Gérard Soula	ALIZE RP
Chairman and CEO	Caroline Carmagnol and Florence Portejoie
contactinvestisseurs@adocia.com	caroline@alizerp.com
Tel.: +33 4 72 610 610	adocia@alizerp.com
	Tel.: + 33 1 44 54 36 61